Skip to main content

Table 1 Demographic, clinical, viral, and laboratory findings of 41 COVID-19 patients for those blood and respiratory specimens were available for SARS-CoV-2 detection

From: SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study

  Overall, N = 41 Sars-CoV-2 in the blood P-value
Present, N = 8 Absent, N = 33
Demographics and clinical characteristics
Age, years 59 (50–67) 65 (41–69) 59 (50–66) 0.469
Sex
Male 13 (30.2) 5 (62.5) 23 (69.7) 0.692
Symptoms
Fever 35 (85.4) 5 (62.5) 30 (90.9) 0.077
Cough 24 (58.5) 3 (37.5) 21 (63.6) 0.172
Dyspnea 28 (68.3) 5 (62.5) 23 (69.7) 0.692
Evidence of interstitial pneumonia 39 (95.1) 7 (87.5) 32 (97.0) 0.356
Chronic comorbidities 27 (65.9) 6 (75.0) 21 (63.6) 0.435
Solid malignancy 5 (12.2) 1 (12.5) 4 (12.1) 0.683
Haematological malignanciesa 6 (14.6) 5 (62.5) 1 (3.0) < 0.001
Diabetes 5 (12.2) 2 (25.0) 3 (9.1) 0.246
Obesity 9 (22.0) 0 (0.0) 9 (23.7) 0.116
Cardiovascular disease 3 (7.3) 2 (25.0) 1 (3.0) 0.092
Chronic obstructive lung disease 4 (9.8) 1 (12.5) 3 (9.1) 0.596
Hypertension 8 (19.5) 1 (12.5) 7 (21.2) 0.503
Chronic kidney disease 1 (2.4) 0 (0.0) 3 (9.1) 0.512
Chronic liver disease 1 (2.4) 0 (0.0) 1 (3.0) 0.805
Otherb 3 (7.3) 0 (0.0) 3 (9.1) 0.512
Immunosuppressive therapy 27 (65.8) 4 (50.0) 23 (69.9) 0.411
SOFA scorec 3 (1–4) 2 (1–4) 3 (1–4)  
 0 5 (12.8) 0 (0.0) 5 (15.6) 0.828
 1–2 12 (30.8) 4 (57.1) 8 (25.0)
 3 8 (20.5) 1 (14.3) 7 (21.9)
  ≥ 4 14 (35.9) 2 (28.6) 12 (37.5)
CHARLSON comorbidity index 2 (1–4) 4 (2–6) 2 (1–3)  
 0 7 (17.1) 1 (12.5) 6 (18.2) 0.298
 1–2 19 (46.3) 2 (25.0) 17 (51.5)
 3–4 8 (19.5) 2 (25.0) 6 (18.2)
  ≥ 5 7 (17.1) 3 (37.5) 4 (12.1)
COVID-19 manifestation
Critical 15 (36.6) 4 (50.0) 11 (33.3) 1.000
Severe 14 (34.1) 2 (25.0) 12 (36.4) 0.692
Moderate 11 (26.8) 2 (25.0) 9 (27.3) 1.000
Mild 1 (2.4) 0 (0) 1 (3.0) 1.000
Time from symptoms-onset to hospital admission, days 5 (3–7) 3 (1–5) 6 (3–8) 0.024
SARS-CoV-2 load, ddPCR
 Respiratory samplesd
  Viral load, copies/mL 3680 (595–166,800) 9,404,000 (586,060-10,000,000) 1560 (312–25,160) 0.002
 Blood samples
  Viral load, copies/mL 0 (0–0) 694 (209–1023) 0 (0–0)
Laboratory findingse
 White blood cell count, ×  109 per L 8.43 (5.59–11.58) 9 (2.70–9.90) 8.30 (5.70–12.50) 0.295
 Lymphocytes count, × 109 per L 0.74 (0.55–1.06) 0.50 (0.40–1.00) 0.80 (0.60–1.10) 0.230
 Platelet count, × 109 per L 155 (78–274) 108 (77–285) 202 (78–274) 0.567
 Total bilirubin, mg/mL 0.47 (0.28–0.66) 0.40 (0.20–0.80) 0.50 (0.30–0.60) 0.574
 Estimated glomerular filtration rate, mL/min 83 (57–99) 57 (46–105) 88 (62–98) 0.806
 Creatinine, μmol/L 85 (70–107) 107 (76–132) 82 (69–98) 0.264
 D-dimer, μg/mL 1.08 (0.70–2.11) 1.20 (0.80–3.20) 1.10 (0.70–1.90) 0.629
 IL-6, pg/mL 53 (16–203) 62 (28–134) 44 (15–251) 0.968
 Lactate dehydrogenase, U/L 320 (220–422) 236 (220–332) 344 (217–552) 0.252
Outcome
 Death 7 (17.1) 4 (50.0) 3 (9.1) 0.018
Time from symptoms-onset to death, days 36 (27–83) 31 (21–42) 83 (28–98) 0.400
 Discharged 34 (82.9) 4 (50.0) 30 (90.9) 0.018
Time from symptoms-onset to discharge, days 50 (33–73) 38 (35–39) 54 (30–77) 0.621
  1. Data are expressed as median (interquartile range), or N (%). P-values comparing COVID-19 patients with evidence of RNAemia to patients without RNAemia were calculated by Mann-Whitney U test, or Fisher’s exact test, as appropriate. P < 0.05 was considered statistical significant. ALT = alanine aminotransferase. AST = aspartate transaminase. COVID-19, coronavirus disease 2019. aIncluding: Large cell lymphoma (n = 4), T-cell lymphoma (n = 1), Hodgkin’s Lymphoma (n = 1). bIncluding: Sarcoidosis (n = 1), Hashimoto’s thyroiditis (n = 1), renal transplantation (n = 1). cInformation available for 39 individuals. d 20 Bronchoalveolar lavages and 21 nasopharingeal swabs. SARS-CoV-2 load did not differ between the two different samples (median, IQR: 3680, 366–166,800 vs 1530, 249–11,230, P = 0.419). eInformation available for 40 individuals
\